研生登革熱mRNA疫苗+新型陽離子脂質獲莫德納前瞻新創獎

第二屆「2024莫德納台灣mRNA前膽新創獎」於11月8日公布獲獎名單，中研院衍生新創公司研生生醫，成功將核酸技術與創新陽離子脂質結合，以脂質奈米粒（LNP）傳輸平台開發出「安全暨有效的登革熱核酸疫苗」，從35組團隊中脫穎而出。

研生生醫榮獲2024莫德納台灣mRNA前瞻新創獎，創新登革熱核酸疫苗備受矚目

利用陽離子脂質開發，專注研發安全有效的mRNA-LNP登革熱疫苗克服常見ADE問題

研生生醫榮獲NBRP Demo Day潛力新秀獎及國際市場獎，兩項大獎加冕

研生生醫在2024年NBRP Demo Day上憑藉抗體新藥AM-928及核心技術，獲得潛力新秀獎和國際市場獎。活動吸引500多位業界人士，研生生醫的成功展示了其全球市場潛力。

AcadeMab announced the initiation of Phase 1 clinical trial of an anti-EpCAM monoclonal antibody, AM-928 for treatment of patients with advanced solid tumors

The first subject of this trail has enrolled, and a total of 30 subjects are expected to participate in this clinical trial

AcadeMab Biomedical and Academia Sinica enter into exclusive license agreement for dengue fever mRNA vaccine and Potent cationic lipids

AcadeMab is making the commitment to human health by providing effective and safer dengue fever vaccine via mRNA technology in the short term.

研生生醫3年抗體新藥進IND 再引mRNA疫苗技術雙引擎發展

研⽣精準醫療抗體新藥AM-928 於年初取得美國IND後，並進一步自中研院引進mRNA疫苗平台成為研生的另一顆引擎。

研生精準醫療抗體新藥AM-928取得美國IND 對多種癌症治療具臨床潛力

研⽣精準醫療抗體新藥AM-928 取得美國IND
對多種癌症治療具臨床潛⼒ 將展開一期臨床試驗

Taiwan's AcadeMab develops groundbreaking therapy for COVID-19 Omicron variant with potent neutralizing efficacy

AcadeMab makes its mark at 2022 BIO USA

Visitors to the 2022 BIO International Convention in San Diego check out at booth of AcadeMab Biomedical Inc. at the Taiwan Pavilionto market the products and seek new business opportunities.